Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Sunitinib-Related Fatigue Occurs Early in RCC Treatment

March 26, 2014
By Leah Lawrence
Article

Patients receiving treatment with sunitinib for advanced renal cell carcinoma experienced worse treatment-related fatigue during the first cycle of treatment with symptoms lessening after subsequent consecutive cycles.

Ball-and-stick model of sunitinib

Ball-and-stick model of sunitinib

Patients receiving treatment with sunitinib for advanced renal cell carcinoma experienced worse treatment-related fatigue during the first cycle of treatment with symptoms lessening after subsequent consecutive cycles, according to the results of a recent study.

“The finding that sunitinib-related fatigue occurs early can be used to enhance education and preparedness among patients who have been prescribed sunitinib for the treatment of advanced renal cell carcinoma,” wrote David Cella, PhD, of Northwestern University Feinberg School of Medicine, and colleagues. “It also highlights the importance of setting upfront expectations regarding the fatigue experience so that patients do not prematurely withdraw from treatment, thereby failing to take advantage of the potential clinical benefit of sunitinib.”

Fatigue is a common problem in patients with advanced cancer assigned treatment with interferon or targeted therapies, such as those commonly used for the treatment of advanced renal cell carcinoma. Previous research has shown that fatigue is reported in as many as 40% to 70% of patients with advanced renal cell disease in clinical trials of sunitinib.

The researchers sought to analyze sunitinib-related fatigue and any effect it has on health-related quality of life. Using data from a phase III trial of sunitinib compared with interferon-alpha in patients with metastatic disease, Cella and colleagues assessed health-related quality of life using the Functional Assessment of Cancer Therapy-Kidney Symptom Index 15-item (FKSI-15) questionnaire, and fatigue using its Disease Related Symptoms subscale (FKSI-DRS) and Common Terminology Criteria for Adverse Events (CTAE).

The researchers then used a repeated-measures model (M1) and a random intercept-slope model (M2) to characterize sunitinib-associated fatigue over time.

The M1 model showed that results of the FKSI-DRS item indicated an increase in patient-reported fatigue during the first cycle of sunitinib. However, fatigue values for the subsequent cycles were numerically better that that of the first.

“Most pairwise comparisons of consecutive CTCAE fatigue cycle means were not found to be statistically significant,” the researchers wrote.

Results from the M2 model supported this finding showing that fatigue was stable over time after the initial increase seen after the first cycle of sunitinib.

Looking at health-related quality of life, the researchers found that the relationship between most quality-of-life outcomes and CTCAE was close to linear regardless of whether the patient was treated with sunitinib or interferon-alpha. As expected, worse health-related quality-of-life scores were found with a higher mean fatigue grade, except for measures that were not linked directly to fatigue such as those related to bone pain.

When looking at the results excluding fatigue, health-related quality of life according to CTCAE was numerically superior with sunitinib compared with interferon-alpha, with a statistically significant difference in most cases.

“Findings similar to those of the current study may have been reported anecdotally by some clinicians, given their experience with sunitinib, but to the best of our knowledge the current study is the first formal analysis to confirm and quantify this observation,” the researchers wrote.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.


Potential Biomarker May Predict Outcomes/Response in RCC

Potential Biomarker May Predict Outcomes/Response in RCC

Kyle Doherty
July 18th 2025
Article

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.


Potential Biomarker May Predict Outcomes/Response in RCC

Potential Biomarker May Predict Outcomes/Response in RCC

Kyle Doherty
July 18th 2025
Article

A new biomarker, KIM-1, has the potential to show outcomes and response for patients with renal cell carcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.